Metropolitan Life Insurance Company (MetLife)’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-9,314
| Closed | -$351K | – | 2957 |
|
|
2021
Q1 | $351K | Hold |
9,314
| – | – | 0.01% | 1645 |
|
|
2020
Q4 | $158K | Buy |
+9,314
| New | +$117K | ﹤0.01% | 2096 |
|
|
2019
Q3 | – | Sell |
-13,283
| Closed | -$80.1K | – | 2653 |
|
|
2019
Q2 | $80.1K | Hold |
13,283
| – | – | ﹤0.01% | 2418 |
|
|
2019
Q1 | $178K | Hold |
13,283
| – | – | ﹤0.01% | 1972 |
|
|
2018
Q4 | $124K | Hold |
13,283
| – | – | ﹤0.01% | 2133 |
|
|
2018
Q3 | $185K | Hold |
13,283
| – | – | ﹤0.01% | 2053 |
|
|
2018
Q2 | $210K | Buy |
13,283
+3,604
| +37% | +$62.9K | ﹤0.01% | 1907 |
|
|
2018
Q1 | $166K | Buy |
9,679
+635
| +7% | +$12.4K | ﹤0.01% | 2007 |
|
|
2017
Q4 | $198K | Sell |
9,044
-10,289
| -53% | -$331K | ﹤0.01% | 1917 |
|
|
2017
Q3 | $791K | Hold |
19,333
| – | – | 0.01% | 1393 |
|
|
2017
Q2 | $582K | Hold |
19,333
| – | – | ﹤0.01% | 1577 |
|
|
2017
Q1 | $699K | Hold |
19,333
| – | – | ﹤0.01% | 1431 |
|
|
2016
Q4 | $969K | Sell |
19,333
-542
| -3% | -$28.5K | 0.01% | 1312 |
|
|
2016
Q3 | $1.04M | Hold |
19,875
| – | – | 0.01% | 1255 |
|
|
2016
Q2 | $822K | Buy |
19,875
+1,908
| +11% | +$83K | 0.01% | 1370 |
|
|
2016
Q1 | $730K | Buy |
17,967
+2,430
| +16% | +$83.5K | 0.01% | 1340 |
|
|
2015
Q4 | $645K | Buy |
15,537
+420
| +3% | +$14.1K | 0.01% | 1460 |
|
|
2015
Q3 | $233K | Hold |
15,117
| – | – | ﹤0.01% | 2177 |
|
|
2015
Q2 | $376K | Buy |
15,117
+1,012
| +7% | +$22.5K | ﹤0.01% | 1949 |
|
|
2015
Q1 | $322K | Hold |
14,105
| – | – | ﹤0.01% | 1798 |
|
|
2014
Q4 | $381K | Hold |
14,105
| – | – | ﹤0.01% | 1954 |
|
|
2014
Q3 | $165K | Hold |
14,105
| – | – | ﹤0.01% | 2512 |
|
|
2014
Q2 | $219K | Buy |
+14,105
| New | +$202K | ﹤0.01% | 2455 |
|
Metropolitan Life Insurance Company (MetLife)'s FPRX Position: Q2 2021 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 9,314 shares — an estimated $351K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in FPRX in Q2 2014 and held it in 23 quarters. The position peaked at $1.04M in Q3 2016. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 9,314 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $351K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Five Prime Therapeutics, Inc. in Q2 2014 and held it in 23 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Five Prime Therapeutics, Inc. position peaked at $1.04M in Q3 2016.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2021, filed 16 Aug 2021.